5-Chlorothiophene-2-Carbonyl Chloride CAS 42518-98-9 Purity >99.5% (GC) Rivaroxaban Intermediate Factory

Short Description:

Chemical Name: 5-Chlorothiophene-2-Carbonyl Chloride

CAS: 42518-98-9

Purity: >99.5% (GC)

Appearance: Pale Yellow Liquid or Pale Yellow Solid

Intermediate of Rivaroxaban (CAS: 366789-02-8)

High Quality, Commercial Production

E-Mail: alvin@ruifuchem.com

Send email to us

Product Detail

Product Tags

Description:

Manufacturer Supply Rivaroxaban Related Intermediates:
(S)-(+)-Glycidyl Phthalimide CAS 161596-47-0
4-(4-Aminophenyl)morpholin-3-one CAS 438056-69-0
Rivaroxaban Intermediate CAS 446292-07-5
5-Chlorothiophene-2-Carboxylic Acid CAS 24065-33-6
5-Chlorothiophene-2-Carbonyl Chloride CAS 42518-98-9
Rivaroxaban API CAS 366789-02-8

Chemical Properties:

Chemical Name	5-Chlorothiophene-2-Carbonyl Chloride
Synonyms	5-Chorothiophene-2-Carbonylchloride; 5-Chloro-2-Thenoyl Chloride
CAS Number	42518-98-9
CAT Number	RF-PI1013
Stock Status	In Stock, Production Scale Up to Tons
Molecular Formula	C5H2Cl2OS
Molecular Weight	181.03
Melting Point	4℃
Specific Gravity (20/20)	1.50
Refractive Index	1.6040 to 1.6080
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Appearance	Pale Yellow Liquid or Pale Yellow Solid
Purity / Analysis Method	>99.5% (GC)
Single Impurity	<0.50%
Total Impurities	<0.50%
Test Standard	Enterprise Standard
Usage	Intermediate of Rivaroxaban (CAS: 366789-02-8)

Package & Storage:

Package: Bottle, 25kg/Drum, or according to customer's requirement.

Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture.

Advantages:

FAQ:

Application:

5-Chlorothiophene-2-Carbonyl Chloride (CAS: 42518-98-9) is used as an intermediate for Rivaroxaban (CAS: 366789-02-8), which is an antithrombotic drug and was developed in a collaboration between the German Bayer Pharmaceuticals and American Johnson company. It is different from the traditional antithrombotic drug heparin in that Rivaroxaban does not need the participation of antithrombin III and can directly antagonize free and bound Xa factors. Heparin requires the effects of antithrombin III, and has no effect on Xa factors in the prothrombin complex. Rivaroxaban is the first oral direct Xa factor inhibitor in the whole world, and it can selectively and competitively inhibit free and bound Da factors as well as prothrombin activity. It uses a dose-dependent method to extend the partial thromboplastin time (PTT) and activated partial thromboplastin time (aPTT) to extend clotting time and lower thrombin genesis. Rivaroxaban has the characteristics of high bioavailability, wide range of target diseases, stable dose-effect relationship, easy oral intake, and low bleeding risk.